Sai Parenterals Secures ₹104.5 Crore Order from Philippines' PILL CORP
Sai Parenterals Limited received a purchase order worth USD 11 million (₹104.50 Crores) from PILL CORP, Philippines. The contract is for supplying anti-TB products for 10 years, starting June 1, 2026.
The order is substantial and international, contributing to revenue and market expansion, but the exact impact on overall financials will depend on future order releases and execution.
The company has secured a large international order, which is a positive development for its business growth and revenue.
Sai Parenterals Limited has announced the receipt of a significant purchase order worth USD 11 million (equivalent to ₹104.50 Crores) from PILL CORP, based in Bulacan, Philippines.
This order entails the supply of anti-TB products to the Philippines market on an exclusivity basis for a period of 10 years. The purchase orders will be released periodically throughout the contract term.
The effective date for this contract is June 1, 2026, and the contract term is ten years from the effective date. It may be revised or terminated with a six-month notice prior to expiry or extended expiry. Neither the promoter, promoter group, nor any group companies of Sai Parenterals Limited have any interest in PILL CORP. Furthermore, this order does not fall within the scope of related party transactions.
The announcement was made on May 28, 2026.
What to do with a filing like this
Sai Parenterals Limited filed this with the NSE as a statutory disclosure, categorised under new orders. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sai Parenterals Limited. Read the original for the full detail.